Understanding EP300 deficiency in ATLL in adults
Official title: Understanding the Implications of EP300 deficiency in Adult T-Cell Leukemia/Lymphoma
Funded at Rutgers Biomedical and Health Sciences · NIH-11270067 · Data updated 2026-11-12
This grant explores how loss of EP300 affects an aggressive adult T-cell cancer (ATLL) to identify new ways to help patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Rutgers Biomedical and Health Sciences NIH-funded |
| Lab location | 1 site (Newark, UNITED STATES) |
| Project start | June 1, 2026 |
| Project end | May 31, 2031 |
| Funding year | 2026 |
| Award (this year) | $672,960 |
| NIH project number | 1R01CA307099-01 |
| Project ID | NIH-11270067 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults with ATLL, especially North American patients with chemo-refractory disease, may benefit from future targeted therapies
✕Less likely to help
Patients without ATLL or without access to participating treatment options may not benefit
What this research studies
ATLL is a serious cancer caused by HTLV-1, with higher urgency in NA-ATLL where outcomes are poor. The project will compare how EP300 loss changes gene activity and epigenetic patterns in ATLL cells to spot potential new targets. Researchers will use patient-derived samples and genome-wide analyses to map where EP300 and related proteins bind in the cancer genome. The findings could point to new therapies that improve survival for patients with ATLL.
Why it matters
Potential benefit: If successful, the work could reveal new therapeutic targets that lead to better treatments and longer survival for ATLL patients.
How similar studies have gone: Prior studies show differing EP300-related patterns in ATLL, suggesting potential for targeted strategies but clinical impact is yet to be demonstrated
Where this research is happening
-
Rutgers Biomedical and Health Sciences
Newark, United States Active
Researchers
- Principal investigator: Madireddy, Advaitha — Rutgers Biomedical and Health Sciences
- Study coordinator: Madireddy, Advaitha
Related research
Other NIH-funded projects on the same topics.
-
Bone marrow grafting and cellular therapies for leukemia and lymphoma
A program at Stanford aims to improve bone marrow transplantation and newer cellular therapies to treat blood cancers like leukemia and lymphoma.
-
Inhibiting T-cell Signaling to Treat Adult ATLL
A study to test whether blocking T-cell receptor signaling can help treat adult T-cell leukemia/lymphoma caused by HTLV-1, potentially improving outcomes for patients.
-
3D gene switches in leukemia and lymphoma
Researchers will map and try to block 3D gene-control hubs that help T-cell leukemia and lymphoma cells grow, aiming to find new ways to help people with these cancers.
-
Improving bone marrow transplants and cell therapies for leukemia and lymphoma
New cell-based treatments and transplant methods aim to make bone marrow transplants safer and help people with leukemia or lymphoma avoid relapse.
-
Targeting T-cell Signals for Adult T-cell Leukemia Lymphoma
This project explores new ways to treat adult T-cell leukemia lymphoma by blocking specific signals within cancer cells.
-
Understanding the causes of Adult T-cell leukemia/lymphoma
This study is looking at Adult T-cell leukemia/lymphoma, a tough cancer that often hits young adults, especially veterans, to find out why some patients don’t respond well to treatment and how we can make those treatments better.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.